Previous Close | 2.6000 |
Open | 2.5700 |
Bid | 2.7900 x 1300 |
Ask | 2.7900 x 1800 |
Day's Range | 2.5000 - 2.5800 |
52 Week Range | 0.9200 - 3.7900 |
Volume | |
Avg. Volume | 4,719,991 |
Market Cap | 620.517M |
Beta (5Y Monthly) | 1.28 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for LXRX
New post hoc analysis of data from Lexicon's (LXRX) phase III study shows improvements in glycemic control when treated with sotagliflozin for type 1 diabetes and chronic kidney disease.
Lexicon (LXRX) delivered earnings and revenue surprises of 13.04% and 3.24%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.